Tennessee-Based Pain Management Group To Close Clinics Amid Financial Turmoil
The CEO of Comprehensive Pain Specialists was indicted in April. Now the group is closing clinics across several states.
The independent source for health policy research, polling, and news.
981-1,000 of 1,320 results
The CEO of Comprehensive Pain Specialists was indicted in April. Now the group is closing clinics across several states.
It’s getting increasingly difficult for patients to afford Truvada, also known as pre-exposure prophylaxis, or PrEP, because of the drug’s high price and insurance company efforts to restrict the use of coupons that shield patients from it.
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
Dr. Mark McClellan joined Johnson & Johnson’s board of directors after leaving the FDA, but the connection often isn’t mentioned in research papers or public events.
Newsletter editor Brianna Labuskes, who reads everything on health care to compile our daily Morning Briefing, offers the best and most provocative stories for the weekend.
As the opioid epidemic rages, a Johns Hopkins surgeon and researcher is leading an effort to curb overprescribing by offering procedure-specific guidelines to ensure that post-surgical patients leave the hospital with enough, but not too much, pain medication.
Purdue Pharma planned an extensive marketing campaign for the launch and promotion of the painkiller OxyContin. Here are Purdue’s internal budget documents from 1996 to 2002 — files released by the Florida attorney general’s office — that detail the company’s early strategy to sell and expand use of the drug.
An inside look at how Purdue Pharma pushed OxyContin despite risks of addiction and fatalities.
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
Sometimes a drug plan’s copayment is higher than the cash price, and under a little-known federal rule, pharmacists have to tell Medicare beneficiaries that — but only if they ask.
More health plans are refusing to count the copayment assistance offered by drug makers as part of the patients’ deductibles or out-of-pocket limits.
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Sarah Kliff of Vox and Alice Ollstein of Talking Points Memo discuss a proposed administration regulation that seeks to separate Planned Parenthood from federal family planning funds, the final congressional passage of legislation aimed at helping those with terminal illnesses obtain experimental medications, and new government reports on the uninsured and federal health spending. Also, Rovner interviews KHN’s Liz Szabo about the May “Bill of the Month.”
The drugmaker agreed to a settlement with the Justice Department over allegations that it funneled copay assistance money through a foundation to Medicare patients.
KHN’s Sarah Jane Tribble explains the key elements of the Trump blueprint on CBS News’ "Red & Blue."
The Trump administration is shaming brand-name drugmakers who refuse to sell samples so generics can be made from their products.
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
The first-in-the-nation measure would empower Vermont to set up a wholesale program to import prescription drugs from Canada. But it still will have to get federal buy-in before it is operational.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Anna Edney of Bloomberg News and Rebecca Adams of CQ Roll Call discuss President Donald Trump’s proposals to control prescription drug prices and the efforts to sell the plan to lawmakers and the public. Also, Rovner interviews emeritus law professor Timothy Jost about the state of the Affordable Care Act.
Last month, U.S. Surgeon General Jerome Adams urged more Americans to carry and learn to use naloxone, which can save someone from an opioid overdose. But the drug, brand-name Narcan, can be difficult to get and expensive.
© 2026 KFF